Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. - Wikidata - awgldk - TriplyDB

Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.

Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.

http://www.wikidata.org/entity/Q33428348

about

Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.

P2860

Q31033443-6BBC32AF-F6BC-4588-BD07-923F89332BDA

P2860

Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.

http://www.wikidata.org/entity/Q33428348

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Capecitabine with/without mito ...... biliary tract adenocarcinoma.

@ast

Capecitabine with/without mito ...... biliary tract adenocarcinoma.

@en

type

label

Capecitabine with/without mito ...... biliary tract adenocarcinoma.

@ast

Capecitabine with/without mito ...... biliary tract adenocarcinoma.

@en

prefLabel

Capecitabine with/without mito ...... biliary tract adenocarcinoma.

@ast

Capecitabine with/without mito ...... biliary tract adenocarcinoma.

@en

P1433

Q33428348-031C0A02-9CA0-443E-9DD0-51283636B753

P1476

Q33428348-8B35EED7-32D9-49CF-B8C5-676AE96CAE0F

P2093

Q33428348-1623012B-2346-49C0-AD7D-C9858217608A

Q33428348-18A4F153-40EC-474F-BE3B-2E35FB90D968

Q33428348-496EE558-3932-43A3-9A33-049E001A9147

Q33428348-503026AB-580D-413A-9EAA-328358E8E74C

Q33428348-503775C1-77AC-46A4-AE4D-F743BBFE3E74

Q33428348-5A034DC2-147B-4EBE-9B8C-65E10021D8CC

Q33428348-758033FB-9DEB-4631-97D2-F0F10B6937F1

Q33428348-858E57FF-F1E2-47D9-9310-9ACF6529EEAC

Q33428348-9A7E05C2-21A8-489A-9A59-0352B7CE35AF

Q33428348-B77FCA79-E640-4E08-8137-0A597AFEDA18

P2860

Q33428348-09DEB036-6C1D-409B-B6E9-9C38AEA6CD03

Q33428348-1565DC1C-18D5-440F-9255-426E4525E677

Q33428348-2194B20D-E957-4CA8-AFFC-47F668D85FFE

Q33428348-2D343DDA-26B7-4776-B641-F7297F809CC7

Q33428348-38A71AFB-78C4-44A4-B108-1431089C094A

Q33428348-443CE520-B9AA-49B8-8430-BFF66F349DF2

Q33428348-46CFB5A2-2A7A-4305-8487-17D7B440ABBE

Q33428348-531FB1AA-D0F6-4A8A-822C-AA39B3A743D3

Q33428348-5D5F7CF2-996E-46D4-AC91-FAFE1BFF3C3E

Q33428348-5DEE82FF-DE85-4B99-B28F-C567C21E1EE5

P2888

Q33428348-EF2316AB-0CF5-46BC-8097-D8E60047486E

P304

Q33428348-D24EDC6B-56AF-4EE1-B703-2D7AE00B59B1

P31

Q33428348-3B18038C-B59F-4FFA-8479-9412F83AA412

P356

Q33428348-96762CBC-C6CB-4A25-B746-68B727820172

P433

Q33428348-5F9C673E-1130-453C-9D26-36B4144EC9EC

P478

Q33428348-03FA29E7-1600-404A-9281-CB0AA796EE20

P50

Q33428348-0C47C210-47F9-42AA-8DE2-537DF52CD3F1

Q33428348-5CBC1B52-9C0F-4F7B-B2B7-5F0E21B6D6B4

P577

Q33428348-2155B8AA-7A44-4A14-ACDB-54DF193DD7D1

P6179

Q33428348-5B72752F-2257-4DE6-9657-8AEEB9DF3DC8

P698

Q33428348-312AE00A-55A0-47B6-A2C0-7B6BF0B88E29

P921

Q33428348-6E33F1CE-4E13-4930-840C-0B7ECA9872EB

P356

S00280-015-2919-0

P1433

Cancer Chemotherapy and Pharmacology

P1476

Capecitabine with/without mito ...... biliary tract adenocarcinoma.

@en

P2093

A Auriemma

http://www.w3.org/2001/XMLSchema#string

A Galiano

http://www.w3.org/2001/XMLSchema#string

A Novarino

http://www.w3.org/2001/XMLSchema#string

B Reinach

http://www.w3.org/2001/XMLSchema#string

C Martines

http://www.w3.org/2001/XMLSchema#string

D Santini

http://www.w3.org/2001/XMLSchema#string

E Vasile

http://www.w3.org/2001/XMLSchema#string

F Leone

http://www.w3.org/2001/XMLSchema#string

G Aprile

http://www.w3.org/2001/XMLSchema#string

L Aldrighetti

http://www.w3.org/2001/XMLSchema#string

P2860

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.

Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.

Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study.

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.

P2888

s00280-015-2919-0

P304

109-114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-015-2919-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1005869890

http://www.w3.org/2001/XMLSchema#string

P698

26659366

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial